Efficacy of proton pump inhibitors for cellular proliferation and apoptosis in Barrett's oesophagus with different mucin phenotypes

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue SUPPL.4, 2006, Pages 41-48

  Amano, Y ^a   Chinuki, D ^b   Yuki, T ^b   Takahashi, Y ^a   Ishimura, N ^b   Kazumori, H ^b   Kushiyama, Y ^b   Karim Rumi, M A ^b   Ishihara, S ^b   Kinoshita, Y ^b  

^a SHIMANE UNIVERSITY HOSPITAL   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYCLINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 ANTIGEN; LANSOPRAZOLE; MUCIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SINGLE STRANDED DNA ANTIGEN; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; BARRETT ESOPHAGUS; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGUS BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

EID: 33846094098     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.00024.x     Document Type: Conference Paper

References (39)

1. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623-8.
2. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44: 700-5.
3. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45: 489-94.
4. Wilkinson SP, Biddlestone L, Gore S, et al. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999; 13: 1205-9.
5. Srinivasan R, Katz PO, Ramakrishnan A, et al. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther 2001; 15: 519-24.
6. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
7. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994; 89: 1844-8.
8. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995; 9: 451-4.
9. Cooper BT, Neumann CS, Cox MA, et al. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12: 893-7.
10. Schell TG. Acid suppression and adenocarcinoma of the esophagus: cause or cure? Am J Gastroenterol 2004; 99: 1884-6.
11. Chinyama CN, Marshall RE, Owen WJ, et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology 1999; 35: 517-24.
12. Guillem P, Billeret V, Buisine MP, et al. Mucin expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer 2000; 88: 856-61.
13. Warson C, Van De Bovenkamp JH, Korteland-Van Male AM, et al. Barrett's esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) and TFF peptides (TFF1 and TFF2), but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. Hum Pathol 2002; 33: 660-8.
14. Kandil HM, Tanner G, Smalley W, et al. Cyclooxygenase-2 expression in Barrett' esophagus. Dig Dis Sci 2001; 46: 785-9.
15. Kaur BS, Khamnehei N, Iravani M, et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 60-7.
16. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122: 1101-12.
17. Zhang W, Wang L, Chang A, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China. Cancer Detect Prev 2003; 27: 243-9.
18. Lagorce C, Paraf F, Vidaud D, et al. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 2003; 42: 457-65.
19. Cheong E, Igali L, Harvey I, et al. Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study. Aliment Pharmacol Ther 2003; 17: 379-86.
20. Amano Y, Kushiyama Y, Ishihara S, et al. Barrett's esophagus with predominant intestinal metaplasia correlates with superficial COX-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by NSAIDs usage. Aliment Pharmacol Ther 2004; 20: 793-802.
21. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
22. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameter Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 1028-32.
23. Fass R, Hell RW, Garewal HS, et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 2001; 48: 310-3.
24. Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol 2001; 33: 306-9.
25. Carton E, Mulligan ED, Keeling PW, et al. Specialized intestinal metaplasia: analysis of prevalence, risk factors and association with gastro-oesophageal reflux disease. Br J Surg 2000; 87: 362-73.
26. Avidan B, Sonnenberg A, Schnell TG, et al. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002; 47: 256-64.
27. Conio M, Filiberti R, Blanchi S, et al. Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 2002; 97: 225-9.
28. Wakelin DE, Al-Mutawa T, Wendel C, et al. A predictive model for length of Barrett's esophagus with hiatal hernia length and duration of esophageal acid exposure. Gastrointest Endosc 2003; 58: 350-5.
29. Avidan B, Sonnenberg A, Schnell TG, et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 1930-6.
30. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
31. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol 1999; 94: 3420-6.
32. Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180: 387-91.
33. El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-83.
34. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-35.
35. Umansky M, Yasui W, Hallak A, et al. PPI reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 2001; 20: 7987-91.
36. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-5.
37. Barham CP, Jones RL, Biddlestone LR, et al. Photothermal laser ablation of Barrett's oesophagus: endoscopic and histological evidence of squamous re-epithelialisation. Gut 1997; 41: 281-4.
38. Van Laethem JL, Cremer M, Peny MO, et al. Eradication of Barrett's esophagus with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-51.
39. Basu KK, Pick B, Bale R, et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut 2002; 51: 776-80.